TNXP → $75.00 by Mar 20, 2028.

$TNXP may be one of the most mispriced small-cap biotech launches right now. TONMYA = 1st new fibromyalgia drug in 15+ years. Company already reported \~4.2k cumulative scripts, \~2.5k patients started, 1.5k+ prescribers very early post-launch. If Symphony is undercounting and the real gap is 1.5x–1.7x (unofficial theory), market may be massively underestimating demand. Bullish YE26 setup: 💎2.2k–3.0k weekly TRx 💎$220M–$300M gross annualized run-rate 💎$160M–$230M 2027 net sales potential 🚀Bull case: $50–$75/share 🚀Blue sky: \~$90 if TONMYA becomes a true …